Immunovant, Inc. IMVT Balance Sheet Statement
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| $902.11M-9.3% | $994.53M+90.6% | $521.87M-12.9% | $598.91M-16.1% | $713.97M+90.6% | ||
| $6.68M-12.5% | $7.63M-7.1% | $8.21M+1.2% | $8.12M-5.6% | $8.6M-27.4% | ||
| $948.82M-9.0% | $1.04B+81.8% | $573.55M-12.0% | $651.76M-15.1% | $767.66M+86.1% | ||
| $443K-16.6% | $531K-16.0% | $632K-14.2% | $737K-12.7% | $844K+12.2% | ||
| $957.01M-9.1% | $1.05B+80.5% | $582.96M-11.9% | $661.44M-14.8% | $776.22M+84.4% | ||
| $7.54M-12.5% | $8.62M+24.6% | $6.92M-11.8% | $7.84M-55.6% | $17.66M-10.9% | ||
| $104.42M+57.6% | $66.26M+4.7% | $63.25M+19.6% | $52.9M-23.1% | $68.78M+0.7% | ||
| $104.42M+57.6% | $66.26M+4.7% | $63.25M+19.6% | $52.9M-23.1% | $68.78M+0.7% | ||
| $20K-100.0% | $500M0.0% | $500M0.0% | $500M+3,124,900% | $16K-100.0% | ||
| -$1.75B-9.3% | -$1.6B-7.4% | -$1.49B-9.3% | -$1.36B-9.7% | -$1.24B-9.4% | ||
| $852.59M-13.5% | $986.14M+89.7% | $519.71M-14.6% | $608.54M-14.0% | $707.45M+101% | ||
| $957.01M-9.1% | $1.05B+80.5% | $582.96M-11.9% | $661.44M-14.8% | $776.22M+84.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Immunovant, Inc.'s total assets?
- Immunovant, Inc. (IMVT) holds $957.0M in total assets, up 23.3% year over year.
- How much debt does Immunovant, Inc. have?
- Immunovant, Inc. carries $72.0K in total debt against $852.6M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Immunovant, Inc. have?
- Immunovant, Inc. holds $902.1M in cash and equivalents.
- Can Immunovant, Inc. cover its short-term obligations?
- Its current ratio is 9.09 — current assets exceed current liabilities.
- Where does Immunovant, Inc.'s balance sheet data come from?
- Every line is extracted from Immunovant, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.